Poorva Singh, Katlin T. Wilson, Linda Varghese, Jimmie Stewart
{"title":"病例报告-玻璃体液中转移性鳞状细胞癌的细胞病理学诊断。","authors":"Poorva Singh, Katlin T. Wilson, Linda Varghese, Jimmie Stewart","doi":"10.1111/cyt.13507","DOIUrl":null,"url":null,"abstract":"<p>Squamous cell carcinoma (SqCC) in the vitreous fluid is exceedingly rare and usually caused by metastasis from primary sites such as lung, breast, and cervix [<span>1-3</span>]. Metastases to the vitreous from other primary sites are even rarer; when they do occur, they are most commonly from cutaneous melanoma in patients previously treated with immune checkpoint inhibitors [<span>4</span>]. Most patients present with vision changes at advanced stages of malignancy with non-specific ocular symptoms, making diagnosis challenging [<span>2</span>]. Given the scarcity of literature on this entity, there are no consensus therapy guidelines for these patients. Reporting individual cases is crucial for expanding the knowledge base, guiding clinical suspicion, and improving management strategies, especially because timely and accurate diagnosis could potentially impact the quality of life of affected patients. Herein, we present a case of oropharyngeal SqCC with metastasis to the vitreous humour.</p><p>Our patient is a 57-year-old male with HPV-associated squamous cell carcinoma of the oropharynx initially diagnosed in 2015. He had multiple local recurrences and metastases to the bone, retroperitoneum, and lung throughout the course of chemoradiotherapy. While on therapy with capecitabine, he developed a sudden decrease in vision and floaters in the left eye and was referred for ophthalmic evaluation. The examination was significant for intraretinal lesions, raising suspicion for panuveitis and posterior cyclitis. A pars plana vitrectomy was performed and sent for cytologic examination wherein the cell block showed a cluster of cells with nuclear enlargement, nuclear membrane irregularities, coarse chromatin, prominent nucleoli, and atypical mitoses (Figure 1A). These cells were strongly and diffusely positive for pancytokeratin and p40 immunohistochemistry (IHC, Figure 1B), raising the suspicion for involvement by the patient's known squamous cell carcinoma. Since ocular adverse effects are common in patients taking anti-metabolite chemotherapeutic drugs such as capecitabine, as was the case in this patient, the clinical suspicion for metastatic disease was low [<span>5</span>]. Consequently, a membrane peel was obtained for corroboration of the cytologic findings. Surgical pathology examination of the epiretinal membrane confirmed the diagnosis of non-keratinising squamous cell carcinoma (Figure 2A) which stained strongly and diffusely with pancytokeratin (Figure 2B) and p16, serving as a surrogate marker for HPV (Figure 2C). The patient was counselled, and he elected to receive intravitreal Melphalan instead of local radiotherapy due to the marginally worse adverse effect profile of radiotherapy.</p><p>Non lymphatic distant metastases to the orbital soft tissue and vitreous humour have been documented to arise predominantly from breast and lung primaries, followed by a few articles reporting cervical SqCC as the primary tumor [<span>1-3</span>], occasional case reports of melanoma and even fewer involving cancer patients treated with immune checkpoint inhibitors<sup>4</sup>. Notably, case reports of SqCC spreading to the vitreous in a non-contiguous manner are few and far between [<span>2, 6-8</span>]. The challenges associated with diagnosing ocular metastasis are compounded by their nonspecific and vague presentation. Most patients with metastatic involvement of the vitreous present with vision changes and sudden onset of floaters usually at advanced stages of malignancy with poor prognosis and adverse clinical outlook<sup>2</sup>. Previous reports mentioned an average survival of 7 months following the diagnosis of ocular metastases in patients with head and neck carcinoma [<span>2, 7, 8</span>]. A similar dismal prognosis has also been demonstrated with other primaries including renal cell carcinoma, where ocular metastasis may serve as the initial sign of systemic dissemination of disease [<span>9</span>]. A recent analysis highlighted the importance of comprehensive evaluation when ocular symptoms are present in patients with an established malignancy, emphasising the importance of addressing both the local and systemic disease burden [<span>4</span>].</p><p>Due to the rarity of these cases, the true incidence of such distant non-lymphatic metastases remains unclear. Consequently, ophthalmologists often maintain a low index of suspicion for this diagnosis when evaluating SqCC patients with vision changes. The only method of establishing a definite diagnosis is vitreous fluid sampling, which is an invasive procedure that many patients with advanced cancer may not consent to, leading to missed diagnoses in a large proportion of cases. The subsequent dearth of documented cases prevents the formulation of consensus therapy guidelines or establishment of clinical trials. A prior study conducted postmortem examination on patients with breast cancer and found that more than one third of cases had ocular metastasis, which was significantly higher than previously reported [<span>10</span>].</p><p>This case highlights that a high index of suspicion should be maintained with ocular cytologic specimens in patients with a history of squamous cell carcinoma. Current literature highlights that timely diagnosis is essential in determining appropriate interventions. Current gaps in the literature include the estimated prognosis following metastasis in the ocular region and analysis of whether initiating radiation/chemotherapeutic interventions increase survival in these types of cases. Further expansion of these studies could include quality of life metrics to inform decision making with regards to risk benefit ratios in the treatment of vitreous metastasis. However, the rarity of these cases hampers the formulation of consensus therapy guidelines. Our case is not only unusual, but is one of the first reports of SqCC of the oropharynx metastasizing to vitreous fluid. Our patient demonstrated significantly worse survival following diagnosis of ocular metastasis compared to the average of 7 months previously reported [<span>2</span>]. The true extent of survival, possible interventions, and improved quality of life measures with poor prognosis all remain to be elucidated with these types of cases. Our case highlights the importance of early diagnosis as patients are typically at later stages of cancer by this point and could benefit from improved therapeutic management to increase quality of life.</p><p><b>Poorva Singh:</b> contributed to the conception of the case report, clinical case selection, and primary drafting of the manuscript. <b>Katlin T. Wilson:</b> conducted literature review, contributed to manuscript writing and revisions, and assisted in formatting and figure preparation. <b>Linda Varghese:</b> provided cytopathologic interpretation, supervised manuscript development, and critically revised the manuscript for intellectual content. <b>Jimmie Stewart:</b> provided cytopathologic interpretation, contributed to case interpretation, and offered critical review and approval of the final manuscript. All authors meet the ICMJE criteria for authorship, have reviewed and approved the final version of the manuscript, and agree to be accountable for its contents.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"36 4","pages":"423-425"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cyt.13507","citationCount":"0","resultStr":"{\"title\":\"Case Report—Cytopathological Diagnosis of Metastatic Squamous Cell Carcinoma in Vitreous Fluid\",\"authors\":\"Poorva Singh, Katlin T. Wilson, Linda Varghese, Jimmie Stewart\",\"doi\":\"10.1111/cyt.13507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Squamous cell carcinoma (SqCC) in the vitreous fluid is exceedingly rare and usually caused by metastasis from primary sites such as lung, breast, and cervix [<span>1-3</span>]. Metastases to the vitreous from other primary sites are even rarer; when they do occur, they are most commonly from cutaneous melanoma in patients previously treated with immune checkpoint inhibitors [<span>4</span>]. Most patients present with vision changes at advanced stages of malignancy with non-specific ocular symptoms, making diagnosis challenging [<span>2</span>]. Given the scarcity of literature on this entity, there are no consensus therapy guidelines for these patients. Reporting individual cases is crucial for expanding the knowledge base, guiding clinical suspicion, and improving management strategies, especially because timely and accurate diagnosis could potentially impact the quality of life of affected patients. Herein, we present a case of oropharyngeal SqCC with metastasis to the vitreous humour.</p><p>Our patient is a 57-year-old male with HPV-associated squamous cell carcinoma of the oropharynx initially diagnosed in 2015. He had multiple local recurrences and metastases to the bone, retroperitoneum, and lung throughout the course of chemoradiotherapy. While on therapy with capecitabine, he developed a sudden decrease in vision and floaters in the left eye and was referred for ophthalmic evaluation. The examination was significant for intraretinal lesions, raising suspicion for panuveitis and posterior cyclitis. A pars plana vitrectomy was performed and sent for cytologic examination wherein the cell block showed a cluster of cells with nuclear enlargement, nuclear membrane irregularities, coarse chromatin, prominent nucleoli, and atypical mitoses (Figure 1A). These cells were strongly and diffusely positive for pancytokeratin and p40 immunohistochemistry (IHC, Figure 1B), raising the suspicion for involvement by the patient's known squamous cell carcinoma. Since ocular adverse effects are common in patients taking anti-metabolite chemotherapeutic drugs such as capecitabine, as was the case in this patient, the clinical suspicion for metastatic disease was low [<span>5</span>]. Consequently, a membrane peel was obtained for corroboration of the cytologic findings. Surgical pathology examination of the epiretinal membrane confirmed the diagnosis of non-keratinising squamous cell carcinoma (Figure 2A) which stained strongly and diffusely with pancytokeratin (Figure 2B) and p16, serving as a surrogate marker for HPV (Figure 2C). The patient was counselled, and he elected to receive intravitreal Melphalan instead of local radiotherapy due to the marginally worse adverse effect profile of radiotherapy.</p><p>Non lymphatic distant metastases to the orbital soft tissue and vitreous humour have been documented to arise predominantly from breast and lung primaries, followed by a few articles reporting cervical SqCC as the primary tumor [<span>1-3</span>], occasional case reports of melanoma and even fewer involving cancer patients treated with immune checkpoint inhibitors<sup>4</sup>. Notably, case reports of SqCC spreading to the vitreous in a non-contiguous manner are few and far between [<span>2, 6-8</span>]. The challenges associated with diagnosing ocular metastasis are compounded by their nonspecific and vague presentation. Most patients with metastatic involvement of the vitreous present with vision changes and sudden onset of floaters usually at advanced stages of malignancy with poor prognosis and adverse clinical outlook<sup>2</sup>. Previous reports mentioned an average survival of 7 months following the diagnosis of ocular metastases in patients with head and neck carcinoma [<span>2, 7, 8</span>]. A similar dismal prognosis has also been demonstrated with other primaries including renal cell carcinoma, where ocular metastasis may serve as the initial sign of systemic dissemination of disease [<span>9</span>]. A recent analysis highlighted the importance of comprehensive evaluation when ocular symptoms are present in patients with an established malignancy, emphasising the importance of addressing both the local and systemic disease burden [<span>4</span>].</p><p>Due to the rarity of these cases, the true incidence of such distant non-lymphatic metastases remains unclear. Consequently, ophthalmologists often maintain a low index of suspicion for this diagnosis when evaluating SqCC patients with vision changes. The only method of establishing a definite diagnosis is vitreous fluid sampling, which is an invasive procedure that many patients with advanced cancer may not consent to, leading to missed diagnoses in a large proportion of cases. The subsequent dearth of documented cases prevents the formulation of consensus therapy guidelines or establishment of clinical trials. A prior study conducted postmortem examination on patients with breast cancer and found that more than one third of cases had ocular metastasis, which was significantly higher than previously reported [<span>10</span>].</p><p>This case highlights that a high index of suspicion should be maintained with ocular cytologic specimens in patients with a history of squamous cell carcinoma. Current literature highlights that timely diagnosis is essential in determining appropriate interventions. Current gaps in the literature include the estimated prognosis following metastasis in the ocular region and analysis of whether initiating radiation/chemotherapeutic interventions increase survival in these types of cases. Further expansion of these studies could include quality of life metrics to inform decision making with regards to risk benefit ratios in the treatment of vitreous metastasis. However, the rarity of these cases hampers the formulation of consensus therapy guidelines. Our case is not only unusual, but is one of the first reports of SqCC of the oropharynx metastasizing to vitreous fluid. Our patient demonstrated significantly worse survival following diagnosis of ocular metastasis compared to the average of 7 months previously reported [<span>2</span>]. The true extent of survival, possible interventions, and improved quality of life measures with poor prognosis all remain to be elucidated with these types of cases. Our case highlights the importance of early diagnosis as patients are typically at later stages of cancer by this point and could benefit from improved therapeutic management to increase quality of life.</p><p><b>Poorva Singh:</b> contributed to the conception of the case report, clinical case selection, and primary drafting of the manuscript. <b>Katlin T. Wilson:</b> conducted literature review, contributed to manuscript writing and revisions, and assisted in formatting and figure preparation. <b>Linda Varghese:</b> provided cytopathologic interpretation, supervised manuscript development, and critically revised the manuscript for intellectual content. <b>Jimmie Stewart:</b> provided cytopathologic interpretation, contributed to case interpretation, and offered critical review and approval of the final manuscript. All authors meet the ICMJE criteria for authorship, have reviewed and approved the final version of the manuscript, and agree to be accountable for its contents.</p><p>The authors declare no conflicts of interest.</p>\",\"PeriodicalId\":55187,\"journal\":{\"name\":\"Cytopathology\",\"volume\":\"36 4\",\"pages\":\"423-425\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cyt.13507\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cyt.13507\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cyt.13507","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
玻璃体液中的鳞状细胞癌(SqCC)极为罕见,通常由原发部位如肺、乳腺和宫颈转移引起[1-3]。从其他原发部位转移到玻璃体的病例更为罕见;当它们确实发生时,它们最常见于先前接受免疫检查点抑制剂[4]治疗的皮肤黑色素瘤患者。大多数患者在恶性肿瘤晚期出现视力改变并伴有非特异性眼部症状,使诊断具有挑战性。鉴于文献的稀缺性,对这些患者没有共识的治疗指南。报告个案对于扩大知识库、指导临床怀疑和改进管理策略至关重要,特别是因为及时和准确的诊断可能会影响受影响患者的生活质量。在此,我们报告一个口咽部SqCC转移到玻璃体的病例。我们的患者是一名57岁男性,于2015年首次诊断为hpv相关的口咽部鳞状细胞癌。在整个放化疗过程中,他有多次局部复发和转移到骨、腹膜后和肺。在卡培他滨治疗期间,他突然出现左眼视力下降和飞蚊症,并被转介进行眼科评估。检查对视网膜内病变有重要意义,引起对全葡萄膜炎和后睫状体炎的怀疑。行玻璃体切除并送细胞学检查,细胞块显示细胞核增大,核膜不规则,染色质粗,核仁突出,有丝分裂不典型(图1A)。这些细胞的全细胞角蛋白和p40免疫组化呈强烈且弥漫性阳性(IHC,图1B),这增加了患者已知的鳞状细胞癌的怀疑。由于服用抗代谢物化疗药物如卡培他滨的患者眼部不良反应很常见,如本例患者,临床对转移性疾病的怀疑较低。因此,获得了膜剥离以证实细胞学结果。视网膜前膜的手术病理检查证实了非角化鳞状细胞癌的诊断(图2A),其泛细胞角蛋白(图2B)和p16染色强烈且弥漫性,作为HPV的替代标志物(图2C)。患者被告知,他选择接受玻璃体内美法兰而不是局部放疗,因为放疗的不良反应更严重。据文献记载,眼眶软组织和玻璃体癌的非淋巴远端转移主要发生在乳房和肺部原发肿瘤,随后有少数文章报道宫颈SqCC为原发肿瘤[1-3],偶尔有黑色素瘤的病例报道,使用免疫检查点抑制剂治疗的癌症患者就更少了。值得注意的是,SqCC以非连续方式扩散到玻璃体的病例报告很少,而且非常少[2,6 -8]。与诊断眼部转移相关的挑战是由于其非特异性和模糊的表现。大多数转移性玻璃体受累的患者通常在恶性肿瘤晚期出现视力改变和突发性飞蚊症,预后差,临床前景不良2。先前的报道提到头颈部癌患者在诊断为眼部转移后的平均生存期为7个月[2,7,8]。其他原发性肾癌也有类似的不良预后,其中眼转移可能是疾病全身传播的最初迹象。最近的一项分析强调了在确定的恶性肿瘤患者出现眼部症状时进行全面评估的重要性,强调了解决局部和全身性疾病负担bbb的重要性。由于这些病例的罕见性,这种远端非淋巴转移的真实发生率尚不清楚。因此,眼科医生在评估有视力改变的SqCC患者时,通常对这种诊断保持低怀疑指数。唯一确定诊断的方法是玻璃体液取样,这是一种侵入性手术,许多晚期癌症患者可能不同意,导致很大比例的病例漏诊。随后文献病例的缺乏阻碍了共识治疗指南的制定或临床试验的建立。先前的一项研究对乳腺癌患者进行了尸检,发现超过三分之一的病例有眼部转移,这一比例明显高于之前报道的[10]。 本病例强调,有鳞状细胞癌病史的患者应保持高度怀疑的眼部细胞学标本。目前的文献强调,及时诊断是确定适当干预措施的关键。目前文献中的空白包括眼区转移后的估计预后,以及分析放射/化疗干预是否能提高这类病例的生存率。这些研究的进一步扩展可能包括生活质量指标,以便为玻璃体转移治疗的风险收益比决策提供信息。然而,这些病例的罕见性阻碍了共识治疗指南的制定。我们的病例不仅是不寻常的,而且是口咽转移到玻璃体液的SqCC的第一个报告之一。与先前报道的平均7个月相比,我们的患者在诊断为眼转移后的生存期明显较差。对于这些类型的病例,生存的真实程度、可能的干预措施和预后不良的生活质量改善措施都有待阐明。我们的病例强调了早期诊断的重要性,因为此时患者通常处于癌症晚期,可以从改进的治疗管理中受益,以提高生活质量。Poorva Singh:对病例报告的构思、临床病例的选择和手稿的初步起草做出了贡献。Katlin T. Wilson:进行文献综述,参与手稿的撰写和修订,并协助排版和图表准备。Linda Varghese:提供细胞病理学解释,监督稿件的发展,并严格修改稿件的知识内容。Jimmie Stewart:提供细胞病理学解释,对病例解释做出贡献,并对最终手稿进行批判性审查和批准。所有作者都符合ICMJE的作者资格标准,已经审阅并批准了稿件的最终版本,并同意对其内容负责。作者声明无利益冲突。
Case Report—Cytopathological Diagnosis of Metastatic Squamous Cell Carcinoma in Vitreous Fluid
Squamous cell carcinoma (SqCC) in the vitreous fluid is exceedingly rare and usually caused by metastasis from primary sites such as lung, breast, and cervix [1-3]. Metastases to the vitreous from other primary sites are even rarer; when they do occur, they are most commonly from cutaneous melanoma in patients previously treated with immune checkpoint inhibitors [4]. Most patients present with vision changes at advanced stages of malignancy with non-specific ocular symptoms, making diagnosis challenging [2]. Given the scarcity of literature on this entity, there are no consensus therapy guidelines for these patients. Reporting individual cases is crucial for expanding the knowledge base, guiding clinical suspicion, and improving management strategies, especially because timely and accurate diagnosis could potentially impact the quality of life of affected patients. Herein, we present a case of oropharyngeal SqCC with metastasis to the vitreous humour.
Our patient is a 57-year-old male with HPV-associated squamous cell carcinoma of the oropharynx initially diagnosed in 2015. He had multiple local recurrences and metastases to the bone, retroperitoneum, and lung throughout the course of chemoradiotherapy. While on therapy with capecitabine, he developed a sudden decrease in vision and floaters in the left eye and was referred for ophthalmic evaluation. The examination was significant for intraretinal lesions, raising suspicion for panuveitis and posterior cyclitis. A pars plana vitrectomy was performed and sent for cytologic examination wherein the cell block showed a cluster of cells with nuclear enlargement, nuclear membrane irregularities, coarse chromatin, prominent nucleoli, and atypical mitoses (Figure 1A). These cells were strongly and diffusely positive for pancytokeratin and p40 immunohistochemistry (IHC, Figure 1B), raising the suspicion for involvement by the patient's known squamous cell carcinoma. Since ocular adverse effects are common in patients taking anti-metabolite chemotherapeutic drugs such as capecitabine, as was the case in this patient, the clinical suspicion for metastatic disease was low [5]. Consequently, a membrane peel was obtained for corroboration of the cytologic findings. Surgical pathology examination of the epiretinal membrane confirmed the diagnosis of non-keratinising squamous cell carcinoma (Figure 2A) which stained strongly and diffusely with pancytokeratin (Figure 2B) and p16, serving as a surrogate marker for HPV (Figure 2C). The patient was counselled, and he elected to receive intravitreal Melphalan instead of local radiotherapy due to the marginally worse adverse effect profile of radiotherapy.
Non lymphatic distant metastases to the orbital soft tissue and vitreous humour have been documented to arise predominantly from breast and lung primaries, followed by a few articles reporting cervical SqCC as the primary tumor [1-3], occasional case reports of melanoma and even fewer involving cancer patients treated with immune checkpoint inhibitors4. Notably, case reports of SqCC spreading to the vitreous in a non-contiguous manner are few and far between [2, 6-8]. The challenges associated with diagnosing ocular metastasis are compounded by their nonspecific and vague presentation. Most patients with metastatic involvement of the vitreous present with vision changes and sudden onset of floaters usually at advanced stages of malignancy with poor prognosis and adverse clinical outlook2. Previous reports mentioned an average survival of 7 months following the diagnosis of ocular metastases in patients with head and neck carcinoma [2, 7, 8]. A similar dismal prognosis has also been demonstrated with other primaries including renal cell carcinoma, where ocular metastasis may serve as the initial sign of systemic dissemination of disease [9]. A recent analysis highlighted the importance of comprehensive evaluation when ocular symptoms are present in patients with an established malignancy, emphasising the importance of addressing both the local and systemic disease burden [4].
Due to the rarity of these cases, the true incidence of such distant non-lymphatic metastases remains unclear. Consequently, ophthalmologists often maintain a low index of suspicion for this diagnosis when evaluating SqCC patients with vision changes. The only method of establishing a definite diagnosis is vitreous fluid sampling, which is an invasive procedure that many patients with advanced cancer may not consent to, leading to missed diagnoses in a large proportion of cases. The subsequent dearth of documented cases prevents the formulation of consensus therapy guidelines or establishment of clinical trials. A prior study conducted postmortem examination on patients with breast cancer and found that more than one third of cases had ocular metastasis, which was significantly higher than previously reported [10].
This case highlights that a high index of suspicion should be maintained with ocular cytologic specimens in patients with a history of squamous cell carcinoma. Current literature highlights that timely diagnosis is essential in determining appropriate interventions. Current gaps in the literature include the estimated prognosis following metastasis in the ocular region and analysis of whether initiating radiation/chemotherapeutic interventions increase survival in these types of cases. Further expansion of these studies could include quality of life metrics to inform decision making with regards to risk benefit ratios in the treatment of vitreous metastasis. However, the rarity of these cases hampers the formulation of consensus therapy guidelines. Our case is not only unusual, but is one of the first reports of SqCC of the oropharynx metastasizing to vitreous fluid. Our patient demonstrated significantly worse survival following diagnosis of ocular metastasis compared to the average of 7 months previously reported [2]. The true extent of survival, possible interventions, and improved quality of life measures with poor prognosis all remain to be elucidated with these types of cases. Our case highlights the importance of early diagnosis as patients are typically at later stages of cancer by this point and could benefit from improved therapeutic management to increase quality of life.
Poorva Singh: contributed to the conception of the case report, clinical case selection, and primary drafting of the manuscript. Katlin T. Wilson: conducted literature review, contributed to manuscript writing and revisions, and assisted in formatting and figure preparation. Linda Varghese: provided cytopathologic interpretation, supervised manuscript development, and critically revised the manuscript for intellectual content. Jimmie Stewart: provided cytopathologic interpretation, contributed to case interpretation, and offered critical review and approval of the final manuscript. All authors meet the ICMJE criteria for authorship, have reviewed and approved the final version of the manuscript, and agree to be accountable for its contents.
期刊介绍:
The aim of Cytopathology is to publish articles relating to those aspects of cytology which will increase our knowledge and understanding of the aetiology, diagnosis and management of human disease. It contains original articles and critical reviews on all aspects of clinical cytology in its broadest sense, including: gynaecological and non-gynaecological cytology; fine needle aspiration and screening strategy.
Cytopathology welcomes papers and articles on: ultrastructural, histochemical and immunocytochemical studies of the cell; quantitative cytology and DNA hybridization as applied to cytological material.